| 1 | Study | 3.45% | |
| 2 | Screens | 1.15% | |
| 3 | Case | 1.15% | |
| 4 | Endocrinopathy | 0.57% | |
| 5 | Animal | 0.57% | |
| 6 | LivaNova’s | 0.57% | |
| 7 | Effectively | 0.57% | |
| 8 | Gut | 0.57% | |
| 9 | Tolerance | 0.57% | |
| 10 | Strategies | 0.57% | |
| 11 | Endocrine | 0.57% | |
| 12 | Office | 0.57% | |
| 13 | Effectiveness | 0.57% | |
| 14 | Non-occlusive | 0.57% | |
| 15 | Resistance | 0.57% | |
| 16 | Evidence | 0.57% | |
| 17 | Antidepressant | 0.57% | |
| 18 | NR2F2 | 0.57% | |
| 19 | Syndrome | 0.57% | |
| 20 | Drug | 0.57% | |
| 21 | Cancer | 0.57% | |
| 22 | Sabah | 0.57% | |
| 23 | Ischemia | 0.57% | |
| 24 | Mesenteric | 0.57% | |
| 25 | Oral | 0.57% | |
| 26 | Could | 0.57% | |
| 27 | Detected | 0.57% | |
| 28 | Title | 0.57% | |
| 29 | Vasculitic | 0.57% | |
| 30 | Endothelial | 0.57% | |
| 31 | Dengue’ | 0.57% | |
| 32 | Modeling | 0.57% | |
| 33 | Deficiency-Related | 0.57% | |
| 34 | Comorbidities | 0.57% | |
| 35 | Nanoparticle | 0.57% | |
| 36 | Assessment | 0.57% | |
| 37 | Regulator | 0.57% | |
| 38 | Prevalence | 0.57% | |
| 39 | Adherence | 0.57% | |
| 40 | Awareness | 0.57% | |
| 41 | UConn | 0.57% | |
| 42 | Therapy | 0.57% | |
| 43 | Validates | 0.57% | |
| 44 | Both | 0.57% | |
| 45 | Organomegaly | 0.57% | |
| 46 | Severe | 0.57% | |
| 47 | Uncover | 0.57% | |
| 48 | Eating | 0.57% | |
| 49 | Al-Qunfudhah | 0.57% | |
| 50 | Patients | 0.57% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||